Its Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint, announced September 3, 2024 (global statistical test 0.08, P = .70)
SYN-AKE: Also called tripeptide-3, it was discovered by Swiss researchers and designed to mimic the effect of waglerin-1, a polypeptide found in the venom of the Temple Viper
Mol Endocrinol (2013) 27(11):196979.10.1210/me.2013-1178 145 BennettAMTangTLSugimotoSWalshCTNeelBG
Methods 3 , 281286 (2006)
Assess Your Reconstitution and Storage Improperly reconstituted or stored GHK-CU can degrade, releasing free copper ions that cause irritation without providing benefits
Choice depends on specific health goals, risk tolerance, budget constraints, and convenience preferences